Pairing a long-acting amylin analog with semaglutide was supposed to be Novo Nordisk's answer to tirzepatide. The REDEFINE program shows a real, large effect — and a head-to-head trial showing it still isn't quite enough.
Cagrisema
-
CagriSema and the Amylin Comeback